Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
𝐍𝐌𝐑𝐀-𝟖𝟔𝟏, a novel muscarinic M4 positive allosteric modulator (PAM) discovered at the Warren Center for Neuroscience Drug Discovery (WCNDD), has entered Phase 1 clinical trials in collaboration with Neumora Therapeutics.